Fiore C, Trézéguet V, Le Saux A, Roux P, Schwimmer C, Dianoux A C, Noel F, Lauquin G J, Brandolin G, Vignais P V
UMR 314 CNRS, Département de Biologie Moléculaire et Structurale, CEA-Grenoble, France.
Biochimie. 1998 Feb;80(2):137-50. doi: 10.1016/s0300-9084(98)80020-5.
Under the conditions of oxidative phosphorylation, the mitochondrial ADP/ATP carrier catalyses the one to one exchange of cytosolic ADP against matrix ATP across the inner mitochondrial membrane. The ADP/ATP transport system can be blocked very specifically by two families of inhibitors: atractyloside (ATR) and carboxyatractyloside (CATR) on one hand, and bongkrekic acid (BA) and isobongkrekic acid (isoBA) on the other hand. It is well established that these inhibitors recognise two different conformations of the carrier protein, the CATR- and BA-conformations, which exhibit different chemical, immunochemical and enzymatic reactivities. The reversible transition of the ADP/ATP carrier between the two conformations was studied by fluorometric techniques. This transconversion, which is only triggered by transportable nucleotides, is probably the same as that which occurs during the functioning of ADP/ATP transport system. The fluorometric approach, using the tryptophanyl residues of the yeast carrier as intrinsic fluorescence probes, was combined to a mutagenesis approach to elucidate the ADP/ATP transport mechanism at the molecular level. Finally, recent reports that myopathies might result from defect in ADP/ATP transport led us to develop a method to quantify the carrier protein in muscular biopsies.
在氧化磷酸化条件下,线粒体ADP/ATP载体催化胞质ADP与线粒体基质ATP通过线粒体内膜进行一对一交换。ADP/ATP转运系统可被两类抑制剂特异性阻断:一类是苍术苷(ATR)和羧基苍术苷(CATR),另一类是 Bongkrekic 酸(BA)和异 Bongkrekic 酸(isoBA)。众所周知,这些抑制剂识别载体蛋白的两种不同构象,即CATR构象和BA构象,它们表现出不同的化学、免疫化学和酶活性。通过荧光技术研究了ADP/ATP载体在两种构象之间的可逆转变。这种仅由可转运核苷酸触发的转构作用,可能与ADP/ATP转运系统功能发挥过程中发生的转构作用相同。利用酵母载体的色氨酸残基作为内在荧光探针的荧光方法,与诱变方法相结合,以在分子水平阐明ADP/ATP转运机制。最后,最近有报道称肌病可能由ADP/ATP转运缺陷引起,这促使我们开发一种方法来定量肌肉活检中的载体蛋白。